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Reporting in this issue of Developmental Cell, L’honore´ et al. (2014) show that a network composed of Pitx2/
Pitx3 and downstream antioxidant enzymes protects differentiating skeletal muscle from excessive reactive
oxygen species production during fetal myogenesis. Genetic deficiency of Pitx2/Pitx3 results in irreversible
oxidative DNA damage and apoptosis, impairing skeletal muscle development.Formation of skeletal muscles is a
complicated task that entails extensive
genome reprogramming of muscle pro-
genitor cells, leading to their functional
specialization into contractile myofibers.
Because skeletal muscles are long-term
living tissues with very low spontaneous
turnover, a major challenge during the
transition from muscle progenitors to
their differentiated progeny is ensuring
that the mechanical and metabolic
activities of postmitotic myofibers are
preserved.
One of the most dramatic events during
skeletal myogenesis is the transition of
muscle progenitors from a proliferative
to an irreversible postmitotic state (Lassar
et al., 1994). This transition is accom-
panied by cell-cycle-related changes
in functional and metabolic activities
(Figure 1). Proliferating cells, which are
constantly exposed to genotoxic stress
generated by the mitogenic environment
and replicative stress during DNA synthe-
sis, are DNA-repair proficient. However,
postmitotic terminally differentiated mus-
cles have a compromised ability to repair
DNA lesions (Narciso et al., 2007). Thus,
the genomic integrity of terminally differ-
entiated muscle is highly dependent on
the accurate repair of DNA lesions in mus-
cle progenitors prior to their differentia-
tion. This surveillance mechanism relies
on the temporal coordination between
DNA repair and activation of the differen-
tiation program. Previous studies have
proposed that a ‘‘myogenic differentiation
checkpoint’’ that prioritizes DNA repair
over the activation of the myogenic pro-
gram in muscle progenitors exposed togenotoxic stress prevents the accumula-
tion of unrepaired DNA lesions in termi-
nally differentiated muscles (Puri et al.,
2002). This checkpoint is based on the
transient inhibition of the transcriptional
activity of MyoD by DNA damage-acti-
vated ABL tyrosine kinase (Puri et al.,
2002), acting until the DNA has been re-
paired, and operates during vertebrate
embryonic myogenesis (Innocenzi et al.,
2011).
Interestingly, during fetal myogenesis
a different source of DNA damage is
provided by the switch from the glyco-
lytic metabolism of proliferating muscle
progenitors to the oxidative phosphory-
lation adopted by postmitotic differenti-
ated muscles. This process generates
elevated levels of reactive oxygen species
(ROS) that cause DNA damage, raising
the question of how differentiating muscle
cells cope with this threat.
In this issue of Developmental Cell,
L’honore´ et al. (2014) show that differenti-
ating fetal muscle progenitors are equip-
ped with antioxidant machinery activated
by Pitx2/Pitx3, downstream targets of
Pax3/Pax7. In response to increased
levels of ROS generated by oxidative
phosphorylation in differentiating mus-
cles, Pitx2/Pitx3 activate a network of
antioxidant genes, including Nrf1 and its
downstream targets Aldh1a1, Mt1,
SOD1, and Gsta1. The authors use a
sophisticated strategy of isolating GFP-
labeled Pax3-expressing cells by flow
cytometry from mouse embryos, taking
advantage of the relative stability of the
Pax3-driven GFP reporter, to separate
undifferentiated Pax3GFP-high from differ-Developmental Celentiating Pax3GFP-low cells. With this pro-
cedure, the authors demonstrate that the
metabolic switch and activation of antiox-
idant genes occurs in Pax3GFP-low differ-
entiating muscle cells expressing muscle
differentiation markers. When isolated
from Pitx2flox/flox:Pitx3flox:R26Rcre-ERT2/+:
Pax3GFP+ embryos treated with 4-hy-
droxytamoxifen to conditionally ablate
Pitx2/Pitx3, differentiating Pax3GFP-low
cells exhibited a higher increase in ROS,
detectable markers of the DNA damage
response (DDR) such as gH2AX foci, and
apoptosis. This accounts for the pheno-
type of Pitx2:Pitx3 double conditional
mutants, which have severe impairment
of skeletal muscle development due
to massive apoptosis of myogenin-
and myosin-expressing cells. Intriguingly,
genetic ablation of Pitx2/Pitx3 driven by
the human skeletal actin (HSA) promoter
(HSA-cre) in postmitotic muscles did not
result in any detectable apoptosis, sup-
porting the conclusion that Pitx2/Pitx3-
dependent regulation of the antioxidant
response is restricted to cells at the onset
of muscle differentiation.
This evidence extends the concept of
the DNA damage-activated differentiation
checkpoint beyond that identified in prolif-
erating myoblasts exposed to genotoxic
stress. It indicates that a further level of
control of the genomic integrity is also at
play during fetal muscle differentiation in
response to the excessive production of
ROSgenerated by oxidative phosphoryla-
tion. In this case, the differentiation
checkpoint relies on two core regula-
tors of the redox response—Pitx2 and
Pitx3—and appears to be specificallyl 29, May 27, 2014 ª2014 Elsevier Inc. 373
Figure 1. Exposure to Genotoxic Stress at Sequential Stages of
Developmental Myogenesis Triggers Stage-Specific Differentiation
Checkpoints
(A) During somitogenesis, migration and expansion of muscle progenitors
expose them to genotoxic stress prior to differentiation. A differentiation
checkpoint holds the differentiation program via transient inactivation of
MyoD, by DNA damage-activated ABL tyrosine kinase, until DNA repair is
completed.
(B) During fetal myogenesis, differentiating muscle progenitors are exposed to
high levels of ROS, generated by the glycolytic-to-oxidative switch. As DNA
repair potential is reduced in differentiating cells, they adopt a different strat-
egy that relies on Pitx2:Pitx3-mediated activation of an antioxidant network
to buffer ROS and prevent unrepairable DNA damage. Failure to activate
this network results in apoptosis of differentiating muscles, leading to severe
disruption of skeletal myogenesis.
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Previewsdirected toward the protec-
tion of fetal myogenesis. The
apoptosis detected in differ-
entiating muscles from Pitx2:
Pitx3 mutants is presum-
ably a safeguard mecha-
nism to prevent formation of
genetically unstable muscles
by eliminating differentiating
muscle cells with unrepair-
able DNA damage caused by
excessive ROS production.
Although the authors assume
that apoptosis is triggered by
ROS-mediated DNA damage,
it is important to note that
muscle differentiation is typi-
cally accompanied by resis-
tance to apoptosis (Latella
et al., 2004), possibly to avoid
the deleterious loss of con-
tractile units. Thus, it remains
possible that Pitx2:Pitx3
also regulate an antiapop-
totic response to DNA dam-
age that is activated in their
absence. Alternatively, resis-
tance to apoptosis could be
a specific property of termi-
nally differentiated myotubes,
with differentiating muscle
cells retaining vulnerability toDNA damage-induced cell death. Indeed,
apoptosis was predominantly detected
in myogenin-positive, mononucleated
cells, suggesting that multinucleation
can confer protection from apoptosis
upon terminally differentiated myotubes.
It should also be noted that the increase
in ROSand consequent apoptosis caused
by genetic deletion of Pitx2:Pitx3 is an
extreme outcome of experimental condi-
tions and may not reflect a physiological
context. Indeed, intracellular ROS regu-
lates a variety of physiological cellular
activities, and fine-tuning of the ROS
rheostat by redox-responsive proteins,
such as SIRT1, can also contribute to the
differentiation checkpoint at earlier stages
of differentiation (Fulco et al., 2003).
This study from L’honore´ et al. (2014)
sheds light on a previously unappreciated
level of ‘‘quality control’’ of skeletal myo-
genesis and suggests that distinct differ-374 Developmental Cell 29, May 27, 2014 ª2entiation checkpoints operate at sequen-
tial stages of developmental myogenesis
to protect the genomic integrity of adult
skeletal muscles (Figure 1). It also raises
interesting questions about the potential
outcomes of failure to activate these
checkpoints. Indeed, the complexity and
redundancy of the regulatory networks
that control the genomic stability of long-
term living, postmitotic tissues such as
skeletal muscles and neurons implies
that disruption of this mechanism could
be implicated in the pathogenesis of adult
diseases. In particular, the association be-
tween defective DNA repair, genomic
instability, age-related functional decline
of tissues and organs, and susceptibility
to degenerative disorders supports the
link between the integrity of ‘‘develop-
mental’’ differentiation checkpoints and
the susceptibility to age-relateddisorders.
In this regard, it is interesting to note that014 Elsevier Inc.Pitx2:Pitx3 have been associ-
ated with age-related degen-
erative disorders that involve
oxidative stress, such as Par-
kinson’s disease, glaucoma,
and cataracts (Amendt et al.,
1998; Luk et al., 2013).
Finally, because Pitx genes
are redeployed in adult myo-
genesis to promote satellite
cell differentiation (Knopp
et al., 2013), which typically
occurs in the highly oxida-
tive regenerative environ-
ment, it will be of interest to
elucidate their potential role
in the ‘‘myogenic differentia-
tion checkpoint’’ that pro-
tects the integrity of regener-
ating muscles.REFERENCES
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